Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dipotassium glycyrrhizinate is the dipotassium salt of glycyrrhizic acid, a compound derived from licorice root (Glycyrrhiza glabra). It is widely used for its anti-inflammatory, antioxidant, anti-allergic, and skin-soothing properties. Mechanistically, it inhibits phospholipase A2 and cyclooxygenase activity—key enzymes in inflammatory pathways—and suppresses the formation of prostaglandins. It also inhibits hyaluronidase and reduces the release of pro-inflammatory mediators such as TNF-alpha and NF-κB translocation. Clinically and cosmetically, it is indicated for chronic hepatitis (to reduce liver inflammation), eczema, dermatitis, rosacea (to soothe inflamed skin), gingival inflammation (oral care), burns/wounds healing support, as well as in products targeting hyperpigmentation due to its ability to inhibit tyrosinase activity involved in melanin synthesis. Additionally reported benefits include hepatoprotective effects and potential antitumorigenic activity[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dipotassium glycyrrhizinate.